 | | Rilpivirine (Edurant, TMC 278) |  | | Published
June 20, 2011; Updated
March 2013 | Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-02-05 | | | Selected References | | 1. | Cohen CJ, Molina JM, Cahn P, et al; ECHO Study Group; THRIVE Study Group. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.J Acquir Immune Defic Syndr. 2012 May 1;60(1):33-42. | |
| 2. | Edurant Prescribing Information. Titusville, NJ: Janssen Therapeutics; 2012. | |
|
|
|
